Allogeneic mesenchymal stem cells

In September 2024, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced two projects that received a subsidy under the "Subsidy scheme for promising care" in 2024 for research on the cost-effectiveness of cold plasma therapy for diabetic foot or venous leg wounds and intranasal mesenchymal stem cells in newborns with hypoxic-ischemic brain damage.

On July 17, 2022, the Austrian Institute for HTA (AIHTA) published four decision support documents, which provide recommendations regarding the inclusion of new medical interventions in the catalog of individual medical services of the performance-oriented hospital financing (Leistungsorientierten Krankenanstaltenfinanzierung, LKF) model, as well as three updates to previous decision support documents.

On 20th of July, 2018, the Austrian HTA body, the Ludwig-Boltzmann Institute (LBI) has published HTA of allogeneic mesenchymal stem cells for Crohn’s disease-associated complex perianal fistulas. Currently, inclusion into Austrian catalogue of benefits was not recommended with reevaluation in 2022.